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Combined injections into experimental tumor nodules of
adenovirus encoding IL-12 and certain chemokines are
capable to induce immune-mediated complete regressions.
In this study, we found that the combination of two
adenoviruses, one encoding IL-12 and other MIP3a (Ad-
CMVIL-12+AdCMVMIP3a) was very successful in treating
CT-26-derived colon carcinomas. However, in experimental
tumors generated from the pancreatic carcinoma cell line
Panc02 such combined treatment induces 50% of macro-
scopic complete regressions, although local relapses within 1
week are almost constant. We derived cell lines from such
relapsing tumors and found that experimental malignancies
derived from their inoculum were not amenable to treatment
in any case with AdCMVIL-12+AdCMVMIP-3a. Importantly,
relapsing cell lines were insensitive to in vitro induction of
apoptosis by IFNg, in clear contrast with the original Panc02
cells. Comparative analyses by cDNA arrays of relapsing cell
lines versus wild-type Panc02 were performed revealing an
important number of genes (383) whose expression levels
were modified more than two-fold. These changes grouped
in certain gene ontology categories should harbor the
mechanistic explanations of the acquired selective resis-
tance to IFNg.
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Introduction
So far, the most promising gene therapy strategies for
cancer are those based upon augmenting the immune
response towards tumor antigens.1,2 Adenovirus-
mediated gene transfer of a number of cytokines inside
the malignant tissue induces tumor regressions in many
models.1,3 Combinations of more than one of the
immunopotentiating genes achieve better results.1,4–12
Some of such synergistic combinations encompass a
chemokine plus a T-cell-activating cytokine to mediate
attraction and activation of infiltrating inflammatory
cells.5–7,13 Gene transfer of IL-12 has shown potent
antitumor activity by itself3,14,15 that can be enhanced
upon combination with lymphotactin,16 IP-105 or Mig.5,6
Macrophage inflammatory protein 3a (MIP-3a) is a
chemokine mainly secreted by activated macrophages,
which interacts with its cognate receptor CCR6 to attract
a number of leukocyte types to inflammatory foci with
selectivity for tisular dendritic cells (DCs).17,18 Gene
transfer of MIP-3a into experimental tumors has been
reported to display antitumor activity and to induce
early infiltration by DCs.19
The most important effector mechanism in these
approaches is the generation of cytotoxic T lymphocytes
(CTLs) capable of destroying tumor cells. To achieve this
goal, CTLs need to recognize specific antigens presented
by MHC class-I molecules20 and to acquire molecular
mechanisms capable of destroying tumor cells, such as
perforin, Fas-L, as well as secretion of cytokines that
induce apoptosis of malignant cells.21,22 However, the
same CTL response can select, among tumor cells, CTL-
insensitive variants that have lost antigens,23,24 antigen-
presenting molecules25 or their susceptibility to the lytic
mechanisms.26,27
Herein, we describe an experimental pancreatic cancer
that relapses because it has lost its susceptibility to IFN-
g-induced apoptosis as a mechanism of escape to gene
transfer treatment with IL-12+MIP-3a. This fact under-
scores the importance of IFN-g as a major antitumor
effector mechanism.28,29
Results
Intratumor gene transfer of IL-12+MIP-3a induces
intensely immunotherapeutic results
In previous reports by our group and others,1,3,5–12,34 the
activity of intratumoral injections of first-generation
recombinant adenovirus encoding IL-12 (AdCMVIL-12)
has been extensively described. For our combination
studies, a similar adenovirus was constructed encodingReceived 6 June 2002; accepted 14 November 2002
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for MIP-3a cDNA under the control of the immediate/
early CMV promoter (AdCMVMIP-3a), as schematically
represented in Figure 1a. CT26 cells infected with
AdCMVMIP-3a at different MOIs released into the tissue
culture supernatant a polypeptide recognized by a
specific mAb in enzyme immune assays (Figure 1b).
According to the hypothesis of attraction/activa-
tion,7,13 we have combined intratumor IL-12 gene
transfer with gene therapy with cDNA encoding for
different chemokines. In CT26-derived tumors that had
grown for 8 days in syngenic BALB/c mice, intratumor
injection of 5 108 PFU of AdCMVMIP-3a induced only
one out of six complete regressions (Figure 2a). In order
to test a possible synergistic effect with IL-12 gene
transfer, we used an intratumoral suboptimal dose5
(7.5 107 PFU) of AdCMVIL-12 that induced regression
in three out of five tumors. Combined injection of
identical doses of both adenoviruses eradicated every
tumor (six out of six), indicating the potency of the
therapeutic combination, that was confirmed in a
repeated experiment shown in Figure 2b in which
AdCMVIL-12 (7.5 107 PFU)+AdCMVMIP3-a (5
108 PFU) caused four out of five tumors to regress,
whereas a similar dose of AdCMVIL-12 cured only one
out of four. In those two experimental groups receiving
subtherapeutical i.t. doses of AdCMVIL-12, IL-12 in-
tratumor concentrations were comparable ranging from
2 to 11 pg/mg of tumor tissue at day 4 after treatment. In
order to exclude transgene-unrelated antitumoral effects
caused by adenovirus combinations, we performed (data
not shown) an additional set of experiments combining
AdCMVIL-12 (7.5 107 PFU)+AdCMVlacZ (5 108 PFU)
that results in the similarly poor antitumoral effects
observed with AdCMVIL-12 alone, thus confirming
results that we have published in a previous work
performed in the same model.5
Intratumor injection of AdCMVIL-12+AdCMVMIP-3a
induces transient macroscopic complete regressions
of experimental pancreatic carcinomas derived from
Panc02 cell line
In our hands, CT26 shows relatively high immunogeni-
city, since its progression in Rag1/ BALB/c mice is
Figure 1 Construction of AdCMVMIP3-a and in vitro production of the
transgene. (a) RT-PCR was used to clone mMIP3-a cDNA from mouse
thymus. MIP3-a cDNA was cloned downstream the CMV promoter and
upstream polyA signal (An) into adenoviral shuttle vector pSQ1
containing the adenoviral packaging signal (C). pSQ1/MIP-3a and
pJM17 were cotransfected into 293 cells by calcium phosphate precipita-
tion generating AdCMVMIP3-a. (b) Direct EIA analysis of MIP3-a
production of cell culture supernatants from untransfected CT26 cells
(control), infected with AdCMVlacZ (MOI: 10 000) or AdCMVMIP3-a at
a MOI of 100, 1000, 5000 and 10 000 as indicated.
Figure 2 Intratumor injection of AdCMVIL-12+AdCMVMIP3-a dis-
plays a potent and synergistic antitumoral effect on CT26 colorectal
carcinomas. BALB/c mice bearing subcutaneous CT26 tumor nodules (4–
5 mm in diameter) were injected intratumorally with saline buffer as
control, 7.5 107 PFU of AdCMVIL-12, 1108 PFU of AdCMVMIP3-a,
or a combination of both adenoviruses at identical doses. Data represent
follow up of the mean diameter of tumor nodules was assessed every 3 days.
The fraction of tumor-free surviving mice 3 months after treatment is
given in each panel. Panels a and b represents two different experiments
similarly done.
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much faster than in BALB/c wild-type mice (Tirapu et al,
manuscript in preparation). Therefore, we moved onto
the Panc02 tumor model, which shows lower intrinsic
immunogenicity in similar experiments. In Panc02-
derived tumors, neither AdCMVIL-12 nor AdCMVMIP-
3a displayed any detectable therapeutic activity (Figure
3). By contrast, combination of both adenoviruses
induces complete regressions in six out of 12 tumors
(three out of six tumors in experiment represented in
Figure 3 and three out of six tumors represented in
Figure 7). Surprisingly, although tumors remained
undetectable by careful palpation and inspection, re-
lapses took place within approximately 1 week after
regression in every case. In C57BL/6 Rag1/ mice,
devoid of T and B-cells, this inhibition of growth never
did take place (0/6), indicating that the effect was
mediated by the adaptative immune system (not shown).
Tumor cell lines derived from relapsing tumors exhibit
phenotypic changes including resistance to IFN-g-
induced apoptosis
Tumors experiencing transient regression upon treat-
ment with AdCMVIL-12+AdCMVMIP-3a, that is, those
described in Figure 3, were explanted and put into cell
culture. Two cell lines derived from Panc02 relapsing
tumors were thus generated and named Panc02-A and
Panc02-B. It was found that Panc02-WT cells showed
different shape and growth pattern in vitro compared to
Panc02-A and Panc02-B. While Panc02-WT tended to
show round aspect and grew in clumped islets, Panc02-A
(Figure 4b) and Panc02-B (Figure 4c) grew displaying a
fusiform shape and a diffuse pattern of growth over the
culture plate (Figure 4). Interestingly, in vitro treatment of
Panc02-A and Panc02-B with a range of IFN-g concen-
trations from 125 to 1000 IU/ml did not cause significant
cell death, in marked contrast with Panc02-WT cells,
which die within 24–48 h through an apoptotic process
(Figure 5a and c).
Under similar conditions, TNF-a failed to induce
apoptosis in both Panc02-WT and derived cell lines,
suggesting specificity of the differential phenotype
(Figure 5b).
Expression of surface IFNg-receptor was found at
similar levels in the three cell lines (Figure 5d). In order
to assess whether there were loss of IFN-g-receptor
proximal signal transduction, we measured the ability of
IFN-g to upregulate MHC class-I expression in Panc02-A
and Panc02-B. It was found that IFN-g readily increases
H-2Kb levels both in Panc02-A and Panc02-B, as well as
in Panc02-WT (not shown and reference 31), indicating
the integrity of IFN-g response at least in this regard
(Figure 5e). Cell death induced by IFN-g in Panc02-WT
was not mediated by Fas-FasL interactions since the
agonistic anti-Fas mAb Jo-2 failed to induce apoptosis
both in Panc02-WT and its derived cell lines, regardless
that Fas was detected by FACS analysis on the surface of
the three cell lines (not shown). In addition, a neutraliz-
ing anti-TRAIL mAb failed to prevent IFNg-induced
death in Panc02-WT (data not shown) that resembles the
cytological features of apoptosis (membrane blebbing,
cell detachment, presence of apoptotic bodies, etc) absent
in similarly treated Panc02-A and B cells (Figure 6a).
However Panc02-A and B were as susceptible as Panc02-
WT to the induction of apoptosis by UV light irradiation,
indicating that the programmed cell death executing
machinery was preserved in the tumor escape variants
(Figure 6b).
The inevitable occurrence of tumor relapse after
treatment with AdCMV-IL12+AdCMVMIP-3a led us to
hypothesize that the escaping IFNg-resistant phenotype
could be already present in the polyclonal Panc02-WT
cells. Indeed, we found that we could routinely raise
IFNg-resistant cells upon culture of serial dilutions of
Panc02-WT in the presence of 1000 IU/ml of the cytokine
after 1–2 weeks (not shown).
Panc02-A and Panc02-B variants are resistant to in
vivo gene transfer with AdCMVIL-12+AdCMVMIP-3a
The cell lines derived from explanted, relapsing Panc02
tumors were also tumorigenic upon subcutaneous injec-
tion in syngenic mice.
Figure 3 In vivo gene transfer of IL-12 and MIP-3a induces transient
macroscopic complete regressions of subcutaneously implanted pancreatic
adenocarcinomas. C57BL/6 mice carrying Panc02 subcutaneous tumor
nodules (4–5 mm in diameter) were treated either with saline buffer as
control (a), 7.5 107 PFU of AdCMVIL-12 (b), 1108 PFU of Ad-
CMVMIP3-a (c), or a combination of both adenoviruses at identical doses
(d). Sizes of tumors were measured every 3 days using. Data are
representative of two independent experiments.
a b c
Figure 4 Tumor cell lines derived from relapsing Panc02 tumors after
treatment with AdCMVIL-12+AdCMVMIP3-a exhibit morphological
changes. Panc02-WT subcutaneous tumor nodules treated with a
combination of AdCMVIL-12+AdMIP3a that had experienced regression
were excised aseptically after relapsed and put into cell culture (see
Materials and methods). Representative fields of phase-contrast microscopy
( 100 magnification) of Panc02-WT (a), and derived cell lines named
Panc02-A (b) and Panc02-B (c) are shown. Panc02-WT cells are sphere
shaped and grow in clumped islets whereas Panc02-A and B grew
displaying a fusiform appearance and displayed a diffuse pattern of growth.
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However, in contrast to tumors derived from the
Panc02-WT cell line (Figure 7a) they were not affected in
their growth by intratumoral injection of 7.5 107 PFU of
AdCMVIL-12+108 PFU of AdCMVMIP-3a (Figure 7b and
c), although pathological examination of treated tumors
disclosed that Panc02-WT showed necrotic areas and
leukocyte infiltration, whereas tumors derived from
Panc02-A did not show such changes upon the same
treatment (not shown).
A potential reason for these differences could be the
variable levels of susceptibility to infection by first
generation recombinant adenovirus in the different lines.
However this reason was ruled out, at least in vitro, since
comparable levels of in vitro gene transduction are
achieved when using similar recombinant adenovirus
encoding b-galactosidase as a reporter gene (Ad-
CMVlacZ) at various MOIs (Figure 7; upper quadrants).
Search for genetic differences in Panc02-WT versus
Panc02-A and Panc02-B
In order to explore gene expression changes that could
explain the phenotype of resistance to IFNg-induced
apoptosis in the escaping cell lines, we performed cDNA
expression arrays (Murine Genome-U74AvZ arrays,
Affimetrix), which combined oligonucleotide probes for
the whole annotated mouse genome plus 6.000 expres-
sion sequence tags (ESTs).
RNA was isolated from cell lines that were 70%
confluent during homogeneous, logarithmic, expansion-
phase in every cell line. The logics to narrow down the
candidate genes to determine the phenotype was to
compare gene expression levels in Panc02-WT with
Panc02-A and with Panc02-B. The gene or genes
responsible for the effect should be up- or down-
regulated both in A and B since both cell lines shared
the distinct phenotype. Only a limited number of genes
was found to be upregulated (91 known genes, and 73
cDNAs or ESTs) or downregulated (137 known genes,
and 82 cDNAs or ESTs) more than two times in Panc02-A
and Panc02-B in comparison with Panc02-WT, as it can
be seen in the dot plot diagram of Figure 8.
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Figure 5 Panc02-WT-derived cell lines (Panc02-A and Panc02-B) are
resistant to IFNg-induced apoptosis in vitro, but IFNg increases their level
of MHC class-I expression. Panc02-WT and its derived cell lines were
plated at 5 104 cells/well in 24-well plates. After 24 h, 125, 250, 500 and
1000 IU/ml of IFNg were added to the cultures. A trypan blue exclusion
dye test was performed 2 days later, showing a clear IFNg dose-dependent
apoptosis in Panc02-WT cells, whereas Panc02-A and B appeared to be
highly resistant (a). Under similar culture conditions, TNF-a cannot
induce apoptosis neither in Panc02-WT nor in derived cell lines (b). (c)
FACs analysis of apoptotic dead cells by PI (Fl-2)/annexin V (Fl-1)
staining in the indicated cell lines treated with 1000 IU/ml of IFNg for
24 h. (d) FACS analysis by indirect immunofluorescence of INFg-receptor
expression in Panc02-WT, A and B cultured cell lines. (e) FACs analysis of
the specific immunostaining H-2Kb of the indicated cell lines cultured with
1000 IU/ml of IFNg (solid histograms) or without this cytokine (empty
histograms).
Figure 6 Panc02-A and B cell lines are resistant to IFNg-induced
apoptosis but susceptible to DNA damage-dependant apoptosis induced by
UV light. (a) Phase contrast microscopy pictures ( 100 magnification) of
Panc02-WT exposed to 500 IU/ml of rmIFNg during 48 h (data are
representative of 10 experiments similarly performed). (b) Phase-contrast
microscopy pictures ( 100 magnification) of Panc02-WT, A and B cells
exposed to UV light (0.360 J/cm2) 12 h prior to the assay.
IFNg-resistant tumors escape IL12+MIP3-a gene therapy
G Mazzolini et al
1070
Gene Therapy
From the microarray experiments, one first notices that
differential expression profiles are quite similar in both
Pan02-A and Pan02-B when compared with Pan02-WT
(see Figure 8). However, in Panc02-A versus Panc02-WT,
the total number of upregulated genes (435) is higher
than that of downregulated sequences (382). This
tendency is inverted when one compares Pan02-B versus
Pan02-WT (255 up and 355 down, respectively). Inter-
estingly, the analysis revealed that common up- or
downregulated genes cluster mainly in three ontological
categories including Cell communication, Cell growth
and/or maintenance, and Developmental processes (see
Figure 9). Within these groups, genes concentrate in four
subcategories, represented by those participating in
responses to external stimulus, cell–cell fusion, metabo-
lism and genetic exchange. A complete list of all genes
included in each GO category is given as Supplementary
Information. Common up- or downregulated genes in
Pan02-A and Pan02-B versus WT are represented in
Figure 9c (left and right, respectively) in which genes
were grouped according to the Biological Process in
which they are involved33 (Figure 9). The identity of the
genes with the highest changes in the relative levels of
expression in Panc02-WT versus Panc02-A and B is
highlighted in Tables 1 (underexpressed genes) and 2
(overexpressed genes).
The two genes showing the extreme up- and down-
fold changes in their levels of expression were analyzed
by quantitative PCR to confirm differential expression in
Panc02-WT versus Panc02-A and Panc02-B. As it can be
seen in Figure 10, clusterin RNA was clearly expressed in
Panc02-WT whereas it was almost completely lost in
Panc02-A and Panc02-B. On the contrary ceruloplasmin
RNA levels were much greater in the case of Panc02-A
and Panc02-B than in Panc02-WT. However, in this case
expression of ceruloplasmin RNA was also detected in
Panc02-WT at levels comparable to the housekeeping
enzyme GAPDH RNA. In other words, ceruloplasmin
seems to have been overexpressed during the transfor-
mation of Panc02-WT cells into the escaping variants
from basal levels. In the case of clusterin results are
compatible with a nearly complete loss of expression.
The intensity of the observed changes with clusterin and
ceruloplasmin RNA concentrations, that are fully con-
sistent with the cDNA microarray data, suggest a role for
these molecules in the apoptotic response to IFNg.
Discussion
The main findings of this study are: (i) The synergistic
antitumoral effect of a combination of recombinant
adenovirus, one encoding MIP-3a and the other IL-12
given intratumorally; (ii) that this combination induces
macroscopic regression of a number of pancreatic
cancers derived from the Panc02 cell line, but relapses
take place constantly; (iii) That cell lines derived from
such relapsing tumors are insensitive to IFNg-induced
apoptosis in vitro, while tumors derived from their
inoculation into syngenic mice are completely insensitive
to the treatment with AdCMV-IL12+AdCMVMIP-3a. An
attempt was also made to identify changes in gene
expression responsible for the relapsing phenotype. This
Figure 7 Panc02-derived cell lines are resistant to gene transfer in vivo with AdCMVIL-12+AdCMVMIP-3a. 2.5 105 Panc02-WT (a), Panc02-A (b)
and Panc02-B (c) cells were injected subcutaneously in syngenic C57BL/6 mice. When tumors reached a diameter above 4–5 mm, animals were treated
intratumorally with 7.5 107 PFU of AdCMVIL-12+1108 PFU of AdCMVMIP3-a. Data represent follow up of the mean diameter of tumor nodules
assessed every 3 days. Data are representative of two independent experiments. Adenoviral transduction efficiency in Panc02-WT, Panc02-A and Panc02-B
cells was evaluated in vitro 24 h after infection with a reporter adenovirus (AdCMVlacZ) (MOI: 500) encoding b-galactosidase gene (upper quadrants).
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Figure 8 Genetic differences between Panc02-WT and derived cell lines in
cDNA expression arrays. Dot-plot diagram display of the relative intensity
of expression of genes analyzed by Affimetrix microarrays in Panc02-A
versus Panc02-WT (left) and Panc02-B versus Panc02-WT (right). Lower
panels are restricted to genes with two or more fold up- or downregulation.
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was analyzed by cDNA microarrays disclosing varia-
tions in a fairly large number of genes, that interestingly
grouped into categories related to cell communication,
cell growth and developmental processes when we used
an informatic tool that classifies genes according to gene
ontology (GO) categories. However, the amount of genes
found makes it unfeasible for any approach to single out
a phenotype-determining gene (in the eventual case that
there existed one).
The idea of combining gene-transfer of a cytokine and
a chemokine is not new.5–7 Several combinations are
successful and there exists a rationale behind it, which is
described as the ‘attraction and activation’ theory7,13.
According to this concept, in our conditions IL-12+MIP3-
a probably helps the induction of tumor-reactive T-
lymphocytes and their infiltration into malignant tissue.
Gene transfer of both IL-123,14,34 and MIP-3a19 is
known to display curative antitumor effects in some
murine models. The former cytokine causes T-cell/NK-
cell immunity35 plus antiangiogenesis,36 while the
second is known for its chemoattractive properties for
immature DCs that are induced to infiltrate the tumors.19
Theoretically, those DC take up antigens from malignant
cells that are transported to lymphoid tissue in a
presentable fashion for responding T-cells. The combina-
tion of MIP-3a+IL-12 had the advantage of letting a
decrease in the dose of IL-12. This is considered
important to avoid the IFNg-mediated toxicity that is
induced by this anticancer agent.37,38 Efficacy of the MIP-
3a+IL-12 combination was comparable to the one
displayed by IL-12+IP10 chemokine against the CT-26
colorectal cancer model.5
IL-12 key functional feature is its ability to induce IFNg
secretion from T-cells, NK cells as well as DC.35,39,40 This
release of IFNg is antigen-independent and is related
both to its therapeutic effects and to its toxicity.35 IFNg is
a major factor produced by cytotoxic-T-lymphocytes
upon encounter with a target tumor cell presenting
cognate antigen.7,31,41 IFNg facilitates antigen recognition
in surrounding cells by promoting MHC class-I expres-
sion42 and it has been recently described that in several
models helps to induce programmed cell death of tumor
cell lines.43–46 Therefore, IFNg, directly or by indirect
mechanisms such as macrophage activation,41 is a
b
a
c
Figure 9 Database analysis by GO categories of the differential gene
expression profile in A and B cell lines versus WT cells: (a) Genes
upregulated (black bars) and downregulated (white bars) in A cells versus
WT cells; (b) Genes upregulated (black bars) and downregulated (white
bars) in B cells versus WT cells; (c) Genes upregulated (black bars) and
downregulated (white bars) in A and B cells versus WT cells. GO
identification codes for the corresponding Biological Process categories as
indicated in the x-axis are: GO: 0008044: adult behavior; GO: 0007626:
locomotory behavior; GO: 0007622: rhythmic behavior; GO: 0007155: cell
adhesion; GO: 0008037: cell recognition; GO: 0007267: cell–cell signaling;
GO: 0009605: response to external stimulus; GO: 0007165: signal
transduction; GO: 0007049: cell cycle; GO: 0016049: cell growth; GO:
0006928: cell motility; GO: 0016043: cell organization and biogenesis;
GO: 0008283: cell proliferation; GO: 0007148: cell shape and size control;
GO: 0006947: cell–cell fusion; GO:0019725: ion homeostasis; GO:
0008152: metabolism; GO: 0007151: sporulation; GO: 0006950: stress
response; GO: 0006810: transport; GO: 0008219: cell death; GO: 0007568:
aging; GO:0030154: cell differentiation; GO: 0007345: embryogenesis and
morphogenesis; GO:0007338: fertilization; GO: 0007276: gametogenesis;
GO: 0009292: genetic exchange; GO: 0030097: hemopoiesis; GO:
0007013: actin modification; GO: 0007599: hemostasis; GO: 0019058:
viral infectious life; GO: 0019048: virus–host interaction.
Table 1 mRNAs underexpressed in Panc02-A and B in comparison to Panc02-WT
Gene bank accession number Fold decrease
Panc02-A Panc02-B
Clusterin D14077 55.4 7.1
CPE-R (clostridium perfingrens receptor) AB000713 53.9 17.8
Ly 49D (killer cell lectin-like receptor) U10090 32.8 8.3
Carbonic anhydrase II M25944 26.6 18.7
MAL proteolipid J07812 24.7 20.5
Laminin gamma-2 U43327 17.2 12.2
Inhibitor DNA-binding 2 (Id-2) AF077861 9.3 2.2
Leukocyte integrin b (CD18) M31039 9 4.2
Keratin complex-1 M36120 13.5 13.9
UcDNA AA592182 14.9 5.1
UcDNA AW123037 14.1 7.3
UcDNA AW04563 12.8 13.9
UcDNA AW124113 8.4 9.8
U: undefined.
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potential effector molecule of the antitumor CTL-
response. We found that a pancreatic carcinoma cell line
escaped AdCMVIL-12+AdCMVMIP-3a intratumoral
therapy precisely because of resistance to IFNg-induced
apoptosis, a prominent feature in the cell line from which
they derived (Panc02-WT). The loss of sensitivity to this
cytokine appears to be selective, since well-known
apoptosis-inducing factors such as TNFa and Fas-L
failed to induce apoptosis in both wild-type and derived
cell lines. The signal pathway from IFNg receptor to gene
expression control in the nucleus seems preserved, since
IFNg readily upregulated MHC class-I expression in the
escaping cell variants as well as in the original cell line.
Therefore, a pathway leading to tumor cell death in
Panc02-WT is interrupted in Panc02-A and Panc0-B.
Moreover, the lost pathway must be independent of the
Stat-1, IRS-1 and CIITA-mediated upregulation of MHC
class I.41 In addition, similar levels of mRNA expression
for those transcription factors were found in Panc02-WT
as well as in A and B variants by microarray analyses
(data not shown). Little is known about the signals that
promote apoptosis after IFNg ligation to IFNgR.47–50 We
are currently exploring signal transduction in these
particular cells regarding apoptosis induction by IFNg.
Table 2 mRNAs overexpressed in Panc02-A and B in comparison to Panc02-WT
Gene bank accession number Fold increase
Panc02-A Panc02-B
Ceruloplasmin U49430 73 60
Gas-1 (growth arrest specific 1) X65128 30 24.9
Leukoprotease inhibitor gene F002719 17.1 5.5
Xanthine dehydrogenase X75129 14 13.9
UcDNA AW208628 11.9 5
Clast-1 AB031386 9.4 5.6
PAF acetylhydrolase U34277 9 11.3
C/EBP (CCAAT enhancer binding protein) X61800 8.3 11
Fibulin extracellular matrix glycoprotein X70853 8.1 11
UcDNA AW124470 8.1 10.3
Epithelial membrane protein-3 U87948 7.7 10.4
U: undefined.
a bclusterin ceruloplasmin
Panc02-WT Panc02-BPanc02-A
clusterin
ceruloplasmin
ng specific RNA
ng RNA/
ng RNA GADPH
ng specific RNA
ng RNA/
ng RNA GADPH
c
1.501+0.05
0.798+0.152
2.068+0.208
1.099+0.110
0.002
0.001
37.995+3.068
23.257+1.878
0.067+0.020
0.089+0.028
47.039+3.214
61.978+4.234
Panc02-WT-RNA (50ng)
Panc02-A-RNA (50ng)
Panc02-B-RNA (50ng)
Panc02-WT-RNA (10ng)
Panc02-B-RNA (10ng)
Panc02-A-RNA (10ng)
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Panc02-A-RNA (50ng)
Panc02-B-RNA (50ng)
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Figure 10 Clusterin and ceruloplasmin RNA levels by real-time RT-PCR (a and b). Real-time RT-PCR curves measuring double-stranded DNA with
SYBR Green fluorescence intensity with specific-primers for clusterin (a) and ceruloplasmin (b) plotted with the number of PCR cycles. Curves with each
templates are indicated with arrows in the graphs. (c) Table showing RNA-quantitative results that were calculated with standard curves performed as in A
and B and referred either as nanograms of specific RNA in 5 mg of total RNA or as a ratio with the quantity of GADPH RNA in each sample. Triplicate
samples were analyzed and mean+standard deviation is provided.
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It is possible that the escaping mutant variants were
already present in the original Panc02-WT population
since in vitro culture of these cells in the presence of IFNg
rendered in week-time colonies growing in the presence
of 1000 IU/ml of IFNg. This favors the interpretation that
the in vivo immunotherapeutic treatment selects out the
escaping variants that were already present as a minority
among Panc02-WT cells.
To identify candidate changes in genes or in proteins
that could explain the resistant phenotype observed in
Panc02-derived cell lines, we reasoned that such varia-
tions should be overexpressed or underexpressed in both
of the escaping cell lines, compared to the wild type. The
tools used for this study included analysis of gene-
expression from cDNA microarrays encompassing
probes for the whole-annotated mouse genome plus a
large number of ESTs. This approach narrowed down the
number of genes, but still an important number of
candidates51 with significant variation of expression
common to both escaping cell lines was substantiated
(up¼164 and down¼219), hence precluding individual
study. In a sense the phenotype could be the result of
only one of such changes or alternatively the result from
the sum of a number of them. We favor the second
interpretation and we analyzed the genes by grouping
them into ontological categories according to the
Biological Process in which they are involved33 (Marti-
nez-Cruz et al, manuscript in preparation that describes
the informatics of algorithms functioning on the data-
bases). Similar classification criteria have been used to
analyze complete genomes52 and changes of gene
expression profiles in transgenic mice.53
From the list of genes with up- or downregulation in
Panc02-A and Panc02-B versus Panc02-WT some of them
had striking fold changes and are the subject of our
current and future research. For instance, among under-
expressed genes we find clusterin (fold changes A versus
WT: 55.4; B versus WT: 7.1). This gene has been
involved both in promotion and protection from apop-
tosis with a still elusive molecular mechanism.54,55
Curiously the receptor for Clostridium perfringens enter-
otoxin (CPE-R) is decreased in its expression (53.9-fold
in A and 17.8-fold in B). This gene is a target for
pancreatic cancer therapy and its function as a putative
transmembrane channel makes it very interesting since
its physiological role is still unknown.56 Carbonic
anhydrase II, MAL protelipid, laminin g2 were also
genes with more than 10-fold downregulation in both
escaping cell lines and deserve future study for their
potential role at changing IFNg susceptibility and/or cell
shape of the tumor cells.
On the contrary, other genes were drastically upregu-
lated among them: ceruloplasmin (73-fold and 60-fold in
A and B, respectively), Gas 1 (growth arrest specific 1)
(fold 30/24.9), xanthine deshydrogenase (14/13.9). These
genes have not obvious involvement in the observed
phenotype, but novel functions could be discovered for
them. Furthermore, ceruloplasmin and xanthine dehy-
drogenase have a role in the defense against oxidative
stress57 that may be involved in the observed resistance
to apoptosis. Besides, platelet activatory factor (PAF)
acetylhydrolase is also upregulated (nine times in A/11.3
times in B); this is also an interesting finding since it has
been recently proposed that this molecule might have
implications in tumor biology.58
It has been recently shown that small changes in
expression results in severe disease.59 Therefore, exces-
sive focusing in the highlighted changes could be
misleading since it cannot be excluded that genes with
small changes may play key roles in promotion and/or
protection from apoptosis. Nonetheless the role played
by those extreme fold changes in the levels of RNA
encoding for clusterin and ceruloplasmin, that have been
confirmed by quantitative PCR, is the matter of our
current research efforts.
We think that other alterations not involving changes
in mRNA expression, such as point mutations that might
alter the function due to production of nonfunctional
proteins, should not be overlooked. These changes are
not addressed by the analysis of cDNA arrays. In
addition, an important number of sequences correspond-
ing to ESTs and cDNAs without assigned function were
differentially expressed in Panc02-WT and escaping
malignant cells. It is possible that a key piece of
information is still missing due to insufficient gene
function knowledge.
In conclusion, beyond describing a successful immu-
notherapeutic gene combination, this study raises a new
concern for immunity-based gene therapy, since it adds a
novel mechanism of tumor escape through the acquisi-
tion of resistance to IFNg-induced apoptosis. Our
attempt to study the gene expression profile of escape
variants showed variation in multiple genes that tend to
group in certain functional categories. Our ongoing and
future research tries to identify the master switch
changes in gene expression that would hierarchically
explain the phenotype of the escaping-malignant cells.
Material and methods
Mice and cell lines
At 5- to 8-week-old C57BL/6 (H2b) and BALB/c (H2d)
female mice were purchased from Harlan (Barcelona,
Spain) and were housed according to institutional
guidelines. The 293 cell line was obtained through
American Type Culture Collection (ATCC) (Manassas,
VA, USA). CT26 tumor cell line is an undifferentiated
murine colorectal adenocarcinoma.14 The mouse pan-
creatic cancer Panc02 was established in C57BL/6 mice
induced by 3-methylcholantrene and presented as a
ductal pancreatic adenocarcinoma.30,31 The subcutaneous
Panc02 tumor tissue was obtained from the National
Cancer Institute, DCTDC Tumor Repository (Frederick,
MD, USA). A cell line was isolated from trypsination of
Panc02 tumor tissue. Panc02 and CT26 cells were
maintained in RPMI 1640 medium containing 10% FCS,
2 mM L-glutamine, 100 U/ml streptomycin, 10 mg/ml
ciprofloxacin and 100 mg/ml penicillin. Cell culture
reagents were from Life Technologies (Basel, Switzer-
land).
Adenovirus construction
The mouse MIP-3a cDNA was generated by an RT-PCR
technique using total RNA extracted from mouse
thymus as template with primers (sense: 50-AC-
CATGGCCTGCGGTGGCAAGCGT-30 and antisense: 50-
GATATCTTACATCTTCTTGACTCTTAG-30) and directly
cloned into pCR2.1-TOPO (Invitrogen, Carlsbad, CA,
USA). The sequence was confirmed by DNA sequencing.
IFNg-resistant tumors escape IL12+MIP3-a gene therapy
G Mazzolini et al
1074
Gene Therapy
The MIP-3a sequence was cloned into adenoviral shuttle
vector pSQ1 with CMV immediate/early promoter up-
stream and polyA sequence downstream of the insertion
site to form pSQ1/MIP-3a. pSQ1/MIP-3a and pJM17
were cotransfected into 293 cells by calcium phosphate
precipitation to obtain AdCMVMIP-3a according to
standard procedures.14 Recombinant adenoviruses carry-
ing the p40 and p35 genes of IL-12 (AdCMVIL-12) or b-
galactosidase (AdCMVlacZ) under the control of CMV
promoter have been previously described.32 Adeno-
viruses were purified by double cesium chloride ultra-
centrifugation and extensively dialyzed against 10 mM
Tris/1 mM MgCl2 prior to be stored at 801C in the
presence of 10% (v/v) glycerol. Titration was made by
plaque assay.32
In vitro MIP-3a production
Supernatants from AdCMVMIP-3a-infected CT26 cells
(3 105 cell/well in 12-well plates) at MOIs 100 and
10 000, as well as noninfected CT26 cells, were collected
48 h after infection. MIP-3a levels were measured by
direct enzyme immunoabsorbent assay (EIA). A 96-well
flat-bottomed microtitration plate (Titertek, ICN Bio-
chemicals INC. Aurora, OH, USA) were coated with
100 ml of different supernatants and standards in
identical medium (recombinant murine MIP-3a, R&D
Systems, Minneapolis, MN, USA) and maintained at 41C
overnight. The plates were washed five times with 100 ml
phosphate-buffered saline (PBS)-Tween (0.05%) and
blocked with 100 ml of PBS containing 10% fetal bovine
serum (FBS) for 2 h at room temperature. After blocking,
the plates were washed in PBS-Tween and incubated for
2 h at room temperature with 100 ml of anti-mouse MIP-
3a (R&D Systems) at final concentration of 2 mg/ml. The
plates were washed five times and further incubated in
PBS-Tween with 10% FBS containing 100 ml of 1:2000
diluted peroxidase-conjugated anti-goat IgG (SIGMA,
Madrid, Spain). After 2 h of incubation at room
temperature, the plates were washed 10 times with
100 ml of PBS-Tween. Color was developed with 100 ml of
tetramethylbenzidine substrate (BD Biosciences Phar-
mingen, San Diego CA) followed by 50 ml of stop
solution (2 N H2SO4). Absorbance (OD) of samples was
read by a Titertek Multiscan II (Flow Laboratories)
microplate reader at 450 nm. Results were determined
in duplicate and expressed as the mean7s.d.
Establishment of subcutaneous model in vivo
Prior to administration of treatment, BALB/c and
C57BL/6 mice were inoculated s.c. in the right hind
flank with 5 105 CT26 or 2.5 105 Panc02-WT tumor
cells in 50 ml of PBS. For treatment, when tumors reach a
diameter above 4–5 mm, subcutaneous tumors were
injected with 50 ml of PBS containing 7.5 107 PFU of
AdCMVIL-12, 5 108 PFU of AdCMVMIP-3a or both.
Similarly, tumors derived from Panc02-A and Panc02-B
cell lines were treated with 7.5 107 PFU of AdCMVIL-
12+5 108 PFU of AdMIP3a or saline. Tumor size (mean
diameter) was assessed using a precision caliper.
Tumor cell lines derived from relapsing tumors
Panc02-WT tumors treated with 7.5 107 PFU of Ad-
CMVIL-12+5 108 PFU of AdMIP3a that experienced
regression and subsequent relapse were excised asepti-
cally and single-cell suspensions were obtained passing
the cells through a mesh and then put into cell culture.
Culture medium was RPMI 1640 supplemented with
10% FCS, 2 mM L-glutamine, 100 U/ml streptomycin,
10 mg/ml ciprofloxacin and 100 mg/ml penicillin. The
two cell lines derived were named Panc02-A and Panc02-
B. Cell culture reagents were from Life Technologies
(Basel, Switzerland).
In vitro IFN-g-induced apoptosis
Panc02-WT, Panc02-A and Panc02-B cells were plated at
5 104 cells/well onto 24-well plates (Greiner Labortech-
nik) and cultured in RPMI 1640 medium to sub-
confluence. After 24 h, cells were incubated at different
concentrations (100–1000 IU/ml) of mrIFN-g (Peprotech.
UK). 36 hs after exposure to IFNg, Tripan blue dye
exclusion test was carried out. UV light induction of
apoptosis was performed by exposure at 0.360 J/cm2
during 60 s in a DNA cross linker device (UVItec
CL508G).
Detection of major histocompatibility complex (MHC)
class-I expression
Suspensions of Panc02-WT, Panc02-A and Panc02-B were
tested for H-2Kb expression by flow cytometry analysis.
Cells were washed with PBS and stained with FITC-
tagged mAb anti-H-2Kb (Pharmingen, San Diego, CA,
USA). Indirect immunofluorescence staining with anti-
IFNg-receptor mAb (Pharmingen) was developed with
FITC-tagged polyclonal anti-rat IgG (Sigma, Barcelona,
Spain). Control staining with irrelevant FITC-tagged rat
mAb was also used. After washing, cells were analyzed
using flow cytometer (Facscallibur, Becton-Dickinson).
FACS analysis of apoptotic cells by annexin-V staining
To detect and quantify apoptosis of both Panc02-WT and
derived cell lines (Panc02-A and Panc02-B) after ex-
posure to rmIFNg at the indicated concentrations cells
were stained with Anexin-V-FLUOS Staining kit (Boher-
inger Mannheim, Germany) according to the manufac-
turer instructions.
In vitro transduction of Panc02-WT, Panc02-A and
Panc02-B cell lines. X-gal staining
We evaluated the in vitro transduction efficiency of the
recombinant adenovirus in Panc02-WT, Panc02-A and
Panc02-B cells using AdCMVlacZ vector. 105 cells in 1 ml
of complete RPMI 1640 medium were seeded in 24-well
plates. After 24 h, cells were infected at different multi-
plicities of infection (100, 500 and 1000) with Ad-
CMVlacZ and incubated at 371C and 5% CO2 for 48 h.
For X-gal staining, cells were fixed in 24-well plates with
glutaraldehyde (0.5%) and stained with 5-bromo-4-
chloro-3-indoyl-beta-galactosidase (X-Gal) as previously
described.32 The experiment was done twice and
triplicates were included.
Gene expression analysis by microarrays
Murine pancreatic cancer Panc02-WT and its derived
Panc02-A and Panco2-B cell lines were grown as
monolayer in RPMI 1640 supplemented with 10% FCS,
2 mM L-glutamine, 100 U/ml streptomycin, 10 mg/ml
ciprofloxacin and 100 mg/ml penicillin. Cells were grown
at 371C in humidified 5% CO2 atmosphere, placed in 15-
cm plates and harvested when at 70–80% confluence.
IFNg-resistant tumors escape IL12+MIP3-a gene therapy
G Mazzolini et al
1075
Gene Therapy
Total RNA was isolated using the Trizol RNA isolation
method (Gibco/BRL) and purified with the Qiagen
RNeasy Mini Kit spin columns (Qiagen). RNA concen-
tration was determined using a spectrophotometer. RNA
integrity was confirmed on a 1% agarose gel electro-
phoresis.
Target preparation
Double-strand DNA was synthesized using the Super-
script Choice System (Gibco/BRL). In all, 10 mg of total
RNA was used in a reverse transcription reaction to
synthesize negative strand cDNA with a primer contain-
ing poly-T and T7 RNA polymerase promoter sequences.
Double-stranded cDNA was phenol–chloroform ex-
tracted and ethanol precipitated. The cDNA was resus-
pended in 12 ml of RNase-free water and 5 ml of the
double-stranded cDNA was used as a template for in
vitro transcription, in the presence of biotinylated UTP
and CTP, to generate labeled antisense RNA. The in vitro
transcription reaction was performed using the Enzo
BioArray High Yield RNA Transcript Labeling Kit (Enzo
Diagnostics). Labeled RNA was purified with the Qiagen
RNeasy Mini Kit spin columns (Qiagen) and quantified
spectrophotometrically.
Array hybridization and scanning
Labeled cRNA was fragmented in fragmentation buffer
(5 buffer: 200 mM Tris-acetate (pH 8.1)/500 mM
KOAc/150 mM MgOAc) and hybridized to the micro-
arrays in 200 ml of hybridization solution containing
15 mg of labeled target in 1 Mes buffer (0.1 M Mes/
1.0 M NaCl/0.01% Tween20/20 mM EDTA) and 0.1 mg/
ml herring sperm DNA. Test2 arrays (Affymetrix) were
hybridized to check the cRNA integrity before the
expression arrays and in all cases the GADPH 30/50 ratio
was below 1.1. Samples were then hybridized on Murine
Genome-U74Av2 Arrays (Affymetrix, USA). This array
represents all sequences (B6000) in the Mouse UniGene
database (Build 74) that have been functionally char-
acterized andB6000 EST clusters. Arrays were rotated at
60 rpm for 16 h at 451C. Following hybridization, the
arrays were washed with 6 SSPE-T (0.9 M NaCl/
60 mM NaH2PO4/6 mM EDTA/0.01% Tween20) at 251C
on a fluidics station (Affymetrix) for 10 2 cycles, and
subsequently with 0.1 M Mes/0.1 M NaCl/0.01%
Tween20 at 501C for 4 15 cycles. The arrays were then
stained with a streptavidin–phycoerythrin conjugate
(Molecular Probes), followed by 10 4 wash cycles. To
enhance the signals, the arrays were further stained with
Anti-streptavidin antibody for 10 min, followed by a 10-
min staining with a streptavidin–phycoerythrin conju-
gate. After 15 4 additional wash cycles, the arrays were
scanned using a confocal scanner (Affymetrix). The
image data were analyzed by Microarray Suite 4.0
(Affymetrix).
Genechip analysis
Using oligonucleotide microarrays, we studied gene
expression profiles of Panc02-A and Panc02-B cell lines
versus Panc02-WT cells, and analyzed those genes
sharing a common up- or downregulation behavior in
the microarray experiments. Those differentially ex-
pressed genes for which a GO code33 is assigned in the
Unigene database (http://www.ncbi.nlm.nih.gov/Lo-
cuslink), were classified according to the Biological
Process in which they participate (Martinez-Cruz et al,
a manuscript in preparation that describes the infor-
matics of algorithms functioning on the databases). Only
entries showing an expression fold change equal or
bigger than 2.0 were considered.
A complete list of all genes included in each GO
category is given as Supplementary Information.
Real-time quantitative RT-PCR
5 mg of total RNA from Panc02-Wt, Panc02-A and
Panc02-B cell lines were DNase I treated (1.2 U/mg
RNA) before cDNA synthesis. One mg of DNase I treated
RNA was used for cDNA synthesis (20 ml) with Super-
Scriptt Rnase H-Reverse Transcriptase (Invitrogen)
(400 U/mg RNA) and 100 pmol oligodT.
Sequences for forward and reverse primers for each
gene are the following: 50CGACTCGCTCCAGGTGGC
CGAGAGGC30 and 50CCACCTCAGTGACACGGGAGG
GGACCTCTGAGT30 for clusterin; 50CCTGGTAATCC
TACAGATGGACAGAGCAAC30 and 50TGGTTTTAGAG
CTTTATTGTAGGAAGGCAG30 for ceruloplasmin; 50AA
GGCTGGGGCTCACCTGAA30 and 50GGCATGGACTG
TGGTCATGAG 30 for GAPDH.
A standard curve, with serial dilutions of cDNA, was
constructed for each sequence. Template concentrations
for reactions in the relative standard were given arbitrary
values of 10, 5, 2.5, 1.25, 0.625, 0.3125 and 0.15625.
Real time PCR reactions were prepared using Light-
Cycler-FastStart DNA master SYBR Green I kit (Roche)
according to the manufacturer instructions. The ampli-
fication program consisted of 1 cycle of 951C with 1 min
hold (‘hot start’) followed by 45 cycles of 951C
(denaturation) with 10-s hold, 601C (annealing) with 5-s
hold, 721C (amplification and acquisition) with 10-s hold.
Melting curve analysis using the program run for one
cycle at 951C with 0-s hold, 651C with 15-s hold, and 951C
with 0-s hold at the step acquisition mode followed
amplification.
The average of triplicate data of each sample was used
to calculate the relative change in gene expression after
normalization target concentration to GAPDH.
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